| 1 |
Piątkowska-Chmiel I, Herbet M, Gawrońska-Grzywacz M, Pawłowski K, Ostrowska-Leśko M, Dudka J. Molecular and neural roles of sodium-glucose cotransporter 2 inhibitors in alleviating neurocognitive impairment in diabetic mice. Psychopharmacology (Berl) 2023;240:983-1000. [PMID: 36869919 DOI: 10.1007/s00213-023-06341-7] [Reference Citation Analysis]
|
| 2 |
Scheen AJ, Bonnet F. Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance? Diabetes Metab 2023;49:101419. [PMID: 36640828 DOI: 10.1016/j.diabet.2023.101419] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 3 |
Atiya A, Das Gupta D, Alsayari A, Alrouji M, Alotaibi A, Sharaf SE, Abdulmonem WA, Alorfi NM, Abdullah KM, Shamsi A. Linagliptin and Empagliflozin Inhibit Microtubule Affinity Regulatory Kinase 4: Repurposing Anti-Diabetic Drugs in Neurodegenerative Disorders Using In Silico and In Vitro Approaches. ACS Omega 2023;8:6423-30. [PMID: 36844587 DOI: 10.1021/acsomega.2c06634] [Reference Citation Analysis]
|
| 4 |
Colbert GB, Madariaga HM, Gaddy A, Elrggal ME, Lerma EV. Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy. Ther Clin Risk Manag 2023;19:133-42. [PMID: 36756278 DOI: 10.2147/TCRM.S398163] [Reference Citation Analysis]
|
| 5 |
Ishikawa J, Harada K. Heart and Brain Failure: The Vicious Cycle of the Heart-Brain Interaction. JACC Asia 2023;3:120-1. [PMID: 36873757 DOI: 10.1016/j.jacasi.2022.10.009] [Reference Citation Analysis]
|
| 6 |
Khedr LH, Eladawy RM, Nassar NN, Saad MAE. Canagliflozin attenuates chronic unpredictable mild stress induced neuroinflammation via modulating AMPK/mTOR autophagic signaling. Neuropharmacology 2023;223:109293. [PMID: 36272443 DOI: 10.1016/j.neuropharm.2022.109293] [Reference Citation Analysis]
|
| 7 |
Ren QW, Katherine Teng TH, Tse YK, Tay WT, Li HL, Tromp J, Yu SY, Hung D, Wu MZ, Chen C, Yuk Yuen JK, Huang JY, Ouwerkerk W, Li XL, Teramoto K, Chandramouli C, Tse HF, Lam CSP, Yiu KH. Incidence, Clinical Correlates, and Prognostic Impact of Dementia in Heart Failure: A Population-Based Cohort Study. JACC Asia 2023;3:108-19. [PMID: 36873768 DOI: 10.1016/j.jacasi.2022.09.016] [Reference Citation Analysis]
|
| 8 |
Wang M, Guan X, Yan J, Michael N, Liu X, Tan R, Lv X, Yan F, Cao Y. Perceptions and responses to cognitive decline in people with diabetes: A systematic review of qualitative studies. Front Public Health 2023;11:1076030. [PMID: 36875353 DOI: 10.3389/fpubh.2023.1076030] [Reference Citation Analysis]
|
| 9 |
Zhou X, Kang C, Hu Y, Wang X. Study on insulin resistance and ischemic cerebrovascular disease: A bibliometric analysis via CiteSpace. Front Public Health 2023;11:1021378. [PMID: 36950100 DOI: 10.3389/fpubh.2023.1021378] [Reference Citation Analysis]
|
| 10 |
Hsieh CY, Sung SF. From Kidney Protection to Stroke Prevention: The Potential Role of Sodium Glucose Cotransporter-2 Inhibitors. Int J Mol Sci 2022;24. [PMID: 36613795 DOI: 10.3390/ijms24010351] [Reference Citation Analysis]
|
| 11 |
Kowalska K, Wilczopolski P, Buławska D, Młynarska E, Rysz J, Franczyk B. The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy. Antioxidants (Basel) 2022;11. [PMID: 36552708 DOI: 10.3390/antiox11122500] [Reference Citation Analysis]
|
| 12 |
Yang L, Zhang X, Wang Q. Effects and mechanisms of SGLT2 inhibitors on the NLRP3 inflammasome, with a focus on atherosclerosis. Front Endocrinol (Lausanne) 2022;13:992937. [PMID: 36589841 DOI: 10.3389/fendo.2022.992937] [Reference Citation Analysis]
|
| 13 |
Sinclair SH, Miller E, Talekar KS, Schwartz SS. Diabetes mellitus associated neurovascular lesions in the retina and brain: A review. Front Ophthalmol 2022;2. [DOI: 10.3389/fopht.2022.1012804] [Reference Citation Analysis]
|
| 14 |
Nakhal MM, Aburuz S, Sadek B, Akour A. Repurposing SGLT2 Inhibitors for Neurological Disorders: A Focus on the Autism Spectrum Disorder. Molecules 2022;27:7174. [DOI: 10.3390/molecules27217174] [Reference Citation Analysis]
|
| 15 |
Wołos-kłosowicz K, Matuszewski W, Rutkowska J, Krankowska K, Bandurska-stankiewicz E. Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy? JCM 2022;11:6183. [DOI: 10.3390/jcm11206183] [Reference Citation Analysis]
|
| 16 |
Heimke M, Lenz F, Rickert U, Lucius R, Cossais F. Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia. Cells 2022;11:3107. [PMID: 36231069 DOI: 10.3390/cells11193107] [Reference Citation Analysis]
|
| 17 |
Hsu SJ, Huang HC, Pun CK, Chang CC, Chuang CL, Huang YH, Hou MC, Lee FY. Sodium-Glucose Cotransporter-2 Inhibition Exacerbates Hepatic Encephalopathy in Biliary Cirrhotic Rats. J Pharmacol Exp Ther 2022;383:25-31. [PMID: 35926870 DOI: 10.1124/jpet.122.001289] [Reference Citation Analysis]
|
| 18 |
Kamel AS, Wahid A, Abdelkader NF, Ibrahim WW. Boosting amygdaloid GABAergic and neurotrophic machinery via dapagliflozin-enhanced LKB1/AMPK signaling in anxious demented rats. Life Sci 2022;:121002. [PMID: 36191679 DOI: 10.1016/j.lfs.2022.121002] [Reference Citation Analysis]
|
| 19 |
Londzin P, Brudnowska A, Kurkowska K, Wilk K, Olszewska K, Ziembiński Ł, Janas A, Cegieła U, Folwarczna J. Unfavorable effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the skeletal system of nondiabetic rats. Biomed Pharmacother 2022;155:113679. [PMID: 36099792 DOI: 10.1016/j.biopha.2022.113679] [Reference Citation Analysis]
|
| 20 |
Sanoudou D, Mantzoros CS, Hill MA. Sodium-glucose cotransporter-2 inhibitors: A treatment option for recurrent vasovagal syndrome? Metabolism 2022;:155309. [PMID: 36067806 DOI: 10.1016/j.metabol.2022.155309] [Reference Citation Analysis]
|
| 21 |
Dong M, Wen S, Zhou L. The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors. Diabetes Metab Syndr Obes 2022;15:2583-97. [PMID: 36035518 DOI: 10.2147/DMSO.S375559] [Reference Citation Analysis]
|
| 22 |
Lin T, Chen Y, Huang J, Liao P, Chen M, Pan L, Jong G. Sodium-glucose co-transporter-2 inhibitors reduce the risk of new-onset stroke in patients with type 2 diabetes: A population-based cohort study. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.966708] [Reference Citation Analysis]
|
| 23 |
Rathmann W, Kostev K. Association of glucose-lowering drugs with incident stroke and transient ischaemic attacks in primary care patients with type 2 diabetes: disease analyzer database. Acta Diabetol 2022. [PMID: 35933524 DOI: 10.1007/s00592-022-01943-7] [Reference Citation Analysis]
|
| 24 |
Nedosugova LV, Markina YV, Bochkareva LA, Kuzina IA, Petunina NA, Yudina IY, Kirichenko TV. Inflammatory Mechanisms of Diabetes and Its Vascular Complications. Biomedicines 2022;10:1168. [DOI: 10.3390/biomedicines10051168] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 25 |
Li S, Yu N, Xu F, Yu L, Yu Q, Fu J. Ginsenoside Rd protects cerebral endothelial cells from oxygen-glucose deprivation/reoxygenation induced pyroptosis via inhibiting SLC5A1 mediated sodium influx. Journal of Ginseng Research 2022. [DOI: 10.1016/j.jgr.2022.05.006] [Reference Citation Analysis]
|
| 26 |
Niu Y, Zhang Y, Zhang W, Lu J, Chen Y, Hao W, Zhou J, Wang L, Xie W. Canagliflozin Ameliorates NLRP3 Inflammasome-Mediated Inflammation Through Inhibiting NF-κB Signaling and Upregulating Bif-1. Front Pharmacol 2022;13:820541. [PMID: 35418866 DOI: 10.3389/fphar.2022.820541] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 27 |
Manu P. Drug Therapy for Unexplained Dyspnea in Post-COVID-19 Fatigue Syndrome: Empagliflozin and Sildenafil. Am J Ther 2022. [PMID: 35412483 DOI: 10.1097/MJT.0000000000001483] [Reference Citation Analysis]
|
| 28 |
Tharmaraja T, Ho JS, Sia C, Lim N, Chong YF, Lim AY, Rathakrishnan RR, Yeo LL, Sharma VK, Tan BY. Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review. Therapeutic Advances in Chronic Disease 2022;13:204062232210869. [DOI: 10.1177/20406223221086996] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 29 |
Chrysant SG, Chrysant GS. Beneficial cardiovascular and remodeling effects of SGLT2 inhibitors: pathophysiologic mechanisms. Expert Rev Cardiovasc Ther 2022. [PMID: 35320057 DOI: 10.1080/14779072.2022.2057949] [Reference Citation Analysis]
|
| 30 |
Hummel J, Kullmann S, Heni M. Spotlight on the Human Brain: Central Actions of SGLT2 Inhibitors? J Clin Endocrinol Metab 2022;107:e3080-1. [PMID: 35323940 DOI: 10.1210/clinem/dgac179] [Reference Citation Analysis]
|
